Safety and tolerability of our A2AR antagonist EXS21546 were confirmed in a HV study, allowing selection of a starting dose for the ongoing IGNITE Phase 1/2 study. IGNITE trial design was based on extensive simulations to enable the most efficient continuous reassessment method settings, and will allow further verification of the patient enrichment biomarker strategy.
almost 2 years ago
P1 data • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • ADORA2A (Adenosine A2a Receptor)